A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures.

Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2012

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2009 Results presented at the Annual Meeting of the American Epilepsy Society.
    • 08 Dec 2009 Changed actual number of patients from 500 to 537 according to an abstract from the Annual Meeting of the American Epilepsy Society.
    • 17 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top